Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Pfizer
(NY:
PFE
)
29.42
-0.24 (-0.81%)
Official Closing Price
Updated: 7:00 PM EDT, Sep 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Pfizer
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
3 No-Brainer Dividend Stocks to Buy in September
September 08, 2024
These stocks pay great dividends and could be long-term winners.
Via
The Motley Fool
Bicycle Therapeutics' Lead Cancer Candidate's Has High-Opportunity, Analyst Initiates With Bullish Tone
September 06, 2024
RBC Capital initiates coverage on Bicycle Therapeutics, highlighting Zelenectide's potential in oncology with improved safety over competitors. The analyst projects ~$2 billion in peak sales by 2033...
Via
Benzinga
FDA Battles Backlog of Drug Factory Inspections Since COVID-19
September 06, 2024
FDA faces inspection backlog with serious public health implications, as critical drug manufacturing plants remain unchecked.
Via
Benzinga
Exposures
Product Safety
What's Going On With Penny Stock Blood Cancer-Focused Vor Biopharma On Friday?
September 06, 2024
Vor Biopharma reveals promising Phase 1/2 study results for AML treatment, and it is planning FDA pivotal trial discussions.
Via
Benzinga
Exposures
Product Safety
A Few Years From Now, You'll Wish You Had Bought This Undervalued Stock
September 06, 2024
This big drugmaker's current challenges present an excellent buying opportunity for forward-thinking investors.
Via
The Motley Fool
A Closer Look at Pfizer's Options Market Dynamics
August 29, 2024
Via
Benzinga
Pfizer's Options Frenzy: What You Need to Know
August 21, 2024
Via
Benzinga
Fake Ozempic Targets Weight-Loss Market: Forged Batches An International Concern
September 05, 2024
Criminals distribute fake Ozempic by forging batch numbers. Novo Nordisk suspects one source in global counterfeiting operation. Other drugs also affected.
Via
Benzinga
Psychedelic Drugs Market Set To Grow By $1.37B By 2028, Driven By Mental Health Disorders And AI Integration
September 05, 2024
The global psychedelic drugs market is projected to grow by USD 1.37 billion by 2028, driven by mental health needs and AI advancements in drug development.
Via
Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Why Walgreens Boots Alliance Fell Another 22% in August
September 05, 2024
The retail pharmacy giant faces ever-mounting headwinds.
Via
The Motley Fool
Ascendis Pharma Faces Challenges With Skytrofa And Yorvipath Pricing: Analysts Weigh In
September 04, 2024
Ascendis Pharma reported disappointing Q2 sales of $38.76 million, missing the consensus of $92.7 million. Key updates included a higher-than-expected U.S. price for Yorvipath and a delayed cash flow...
Via
Benzinga
UK, Taiwan Approve Moderna's Updated COVID-19 Shot
September 03, 2024
The Medicines and Healthcare Products Regulatory Agency has approved Moderna's updated COVID-19 vaccine targeting the JN.1 variant, available for eligible groups through the NHS autumn program and for...
Via
Benzinga
Exposures
COVID-19
Pfizer And Valneva Partnered Lyme Disease Vaccine Shows Effectiveness As Booster Shot In Mid-Stage Study
September 03, 2024
Valneva and Pfizer released data from their Phase 2 study of the Lyme disease vaccine candidate VLA15, showing strong immune response and safety profile after a second booster dose, with seroconversion...
Via
Benzinga
Vaxcyte, Shoals Technologies, Polestar Automotive, Applied Optoelectronics And Other Big Stocks Moving Higher On Tuesday
September 03, 2024
Via
Benzinga
Bacterial Infections Vaccine Developer Vaxcyte's Pneumococcal Shot Shows Promise in Mid-Stage Trial, Stock Shoots Higher
September 03, 2024
Vaxcyte announced positive topline results from its Phase 1/2 study of VAX-31, a 31-valent pneumococcal conjugate vaccine candidate, showing strong immune responses and safety comparable to Pfizer's...
Via
Benzinga
Vaxcyte Catapults 34% As It Looks To Take On Pfizer In A $10 Billion Market
September 03, 2024
The company is looking to take on Pfizer in the massive pneumococcal conjugate vaccine market.
Via
Investor's Business Daily
Why Is BridgeBio Pharma Stock Trading Higher On Friday?
August 30, 2024
BridgeBio Pharma presented additional data from its Phase 3 ATTRibute-CM study of acoramidis in ATTR-CM at the European Society of Cardiology 2024, showing increased serum TTR levels in participants...
Via
Benzinga
Alnylam Pharmaceuticals Stock Falls After Detailed Vutrisiran Data For A Condition With Stiff Heart Muscles
August 30, 2024
Alnylam Pharmaceuticals shares drop as detailed results from the HELIOS-B Phase 3 study of vutrisiran for ATTR-CM reveal mixed outcomes. Reductions in mortality and cardiovascular events were presented...
Via
Benzinga
Alnylam Plummets, Reversing 50% Gain This Year, As Pfizer Rival Lags Expectations
August 30, 2024
The company is hoping to rival Pfizer's approved treatment for cardiomyopathy.
Via
Investor's Business Daily
2 Incredibly Cheap Growth Stocks to Buy Now
August 30, 2024
The market has been tougher on these companies than some, but that could be a golden opportunity for the right investor.
Via
The Motley Fool
2 Incredibly Cheap Healthcare Stocks to Buy Now
August 30, 2024
Top healthcare stocks are a great addition to any portfolio.
Via
The Motley Fool
The 9 Pharma Stocks To Watch — Including Viking, Roche And Amgen — Amid The Fast-Growing Obesity Drug Race
August 29, 2024
The race to develop the next big obesity treatment is on with leaders Lilly and Novo trying to keep their top slots.
Via
Investor's Business Daily
2 Beaten-Down S&P 500 Dividend Stocks to Buy on the Dip and Hold Forever
August 28, 2024
These underappreciated dividend payers offer yields above 4% at recent prices.
Via
The Motley Fool
Topics
Stocks
Exposures
US Equities
3 Ways the Democratic Party's Platform Could Impact Biotech and Pharma Stocks if Implemented
August 27, 2024
There's no reason to succumb to gloom and doom here.
Via
The Motley Fool
Americans To Access COVID-19 Test Kits For Free As US Government Restarts Free At-Home Program
August 26, 2024
US households can order free COVID-19 tests starting in late September as the government reopens the program ahead of the fall virus season.
Via
Benzinga
Exposures
COVID-19
Is Pfizer Stock Still a Buy After an Unexpected Setback?
August 26, 2024
Its long-term growth plan just hit a small bump in the road.
Via
The Motley Fool
Want $2,000 in Annual Dividends? Invest $30,000 in These 3 High-Yielding Stocks
August 24, 2024
Before interest rates come down, you may want to consider loading up on these terrific income stocks.
Via
The Motley Fool
Novo Nordisk's Ozempic Might Be Among 2027 Medicare Price Negotiation Targets
August 23, 2024
Analysts expect Novo Nordisk's Ozempic and other major drugs to be included in 2027 Medicare price negotiations. Despite concerns, experts predict limited financial impact on companies like Pfizer,...
Via
Benzinga
FDA Approves Updated COVID Vaccines From Pfizer And Moderna, But Leaves Out Novavax's Shot
August 22, 2024
The FDA granted emergency use authorization for updated mRNA COVID-19 vaccines targeting the Omicron KP.2 strain, including new formulas from Moderna and Pfizer/BioNTech. These vaccines, designed to...
Via
Benzinga
Exposures
COVID-19
Product Safety
2 Cheap Passive Income Stocks to Buy Now
August 20, 2024
Passive income stocks offer potential for steady returns and financial security in retirement.
Via
The Motley Fool
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.